logo

Aerie Pharmaceuticals, Inc. (AERI)



Trade AERI now with
  Date
  Headline
4/1/2019 6:43:02 AM Aerie Appoints Gianluca Corbinelli As Chief Commercial Officer - Europe
3/25/2019 6:34:20 AM Aerie Pharma Names David Ellis Director, Chemistry; Angela Justice As Western Regional Director, Medical Science Liaison
3/21/2019 6:33:08 AM Aerie Pharma Begins Netarsudil Ophthalmic Solution Phase 2 Clinical Trial In Japan
3/18/2019 6:34:53 AM Aerie Pharma Begins Phase 2 Clinical Trial Of AR-1105 For Macular Edema Associated With Retinal Vein Occlusion
1/17/2019 6:35:00 AM Aerie Pharmaceuticals Reports Acceptance Of Investigational NDA For AR-1105
1/4/2019 6:31:10 AM Aerie Pharmaceuticals Announces Positive Topline Results Of Netarsudil Ophthalmic Solution In Pilot Phase 2 Study
1/2/2019 6:33:06 AM Aerie Pharma Appoints Ami Bavishi As Director, Investor Relations
10/9/2018 6:33:42 AM Aerie Pharma: EMA To Begin Review Of MAA For Rhokiinsa 0.02%
9/12/2018 4:01:31 PM Aerie Pharmaceuticals Appoints David Gryska To Board Of Directors
9/11/2018 4:04:17 PM Aerie Pharmaceuticals Appoints Robert Finan As Director Of Finance
9/10/2018 6:30:43 AM Aerie Pharmaceuticals Appoints Thomas Shepard As VP, Implant Manufacturing
8/20/2018 6:31:07 AM Aerie Appoints Jeffrey White As Director, Toxicology And Pharmacokinetics
8/15/2018 6:34:17 AM Aerie Announces Topline Efficacy Results From Study Designed To Evaluate Effect Of Rhopressa
8/1/2018 6:41:16 AM Aerie And DSM Biomedical Expand Collaborative Research, Development, And License Agreement
7/23/2018 6:33:43 AM Aerie Pharma Announces Early Notification Of FDA Acceptance Of NDA Submission For Roclatan
7/16/2018 6:31:16 AM Aerie Pharmaceuticals Announces Appointment Of Randall Brown As Director, Payer Marketing
5/15/2018 6:32:56 AM Aerie Pharmaceuticals Submits NDA To FDA For Roclatan (netarsudil/latanoprost Ophthalmic Solution) 0.02%/0.005%
5/1/2018 6:31:35 AM Aerie Appoints Concetta Perro As Commercial Counsel
4/30/2018 6:32:26 AM Aerie Announces U.S. Launch Of Rhopressa (netarsudil Ophthalmic Solution) 0.02%